Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma-Reference-Cited by-同舟云学术

Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma

Published:2015-01-29 Issue:3 Volume:3 Page:278-287
ISSN:2326-6066
Container-title:Cancer Immunology Research
language:en
Short-container-title:Cancer Immunol Res

Author:

Sabado Rachel Lubong,Pavlick Anna,Gnjatic Sacha,Cruz Crystal M.,Vengco Isabelita,Hasan Farah,Spadaccia Meredith,Darvishian Farbod,Chiriboga Luis,Holman Rose Marie,Escalon Juliet,Muren Caroline,Escano Crystal,Yepes Ethel,Sharpe Dunbar,Vasilakos John P.,Rolnitzsky Linda,Goldberg Judith D.,Mandeli John,Adams Sylvia,Jungbluth Achim,Pan Linda,Venhaus Ralph,Ott Patrick A.,Bhardwaj Nina

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Immunology

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomimetic Nanomodulators With Synergism of Photothermal Therapy and Vessel Normalization for Boosting Potent Anticancer Immunity;Advanced Materials;2024-08-23

2. Nanofluidic delivery implant sustains localization and maximizes efficacy of intratumoral immunotherapy;Nano Today;2024-06

3. When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?;Pharmacological Research;2024-05

4. In vivo visualization of tumor-associated macrophages re-education by photoacoustic/fluorescence dual-modal imaging with a metal-organic frames-based caspase-1 nanoreporter;Journal of Colloid and Interface Science;2024-04

5. Harnessing innate immune pathways for therapeutic advancement in cancer;Signal Transduction and Targeted Therapy;2024-03-25